{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:22:37Z","timestamp":1793330557078,"version":"4.5.0"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,9,1]]},"DOI":"10.2169\/internalmedicine.0318-22","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:57:48Z","timestamp":1693508268000},"page":"2547-2551","source":"Crossref","is-referenced-by-count":6,"title":["Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm"],"prefix":"10.2169","volume":"62","author":[{"given":"Yasuhiro","family":"Nagate","sequence":"first","affiliation":[{"name":"Department of Hematology, National Hospital Organization Osaka National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nakaya","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Osaka National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Kamimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Osaka National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nojima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Osaka National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Jacob MC, Chaperot L, Mossuz P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 88: 941-955, 2003."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Pagano L, Valentini CG, Pulsoni A, et al; GIMEMA-ALWP (Gruppo Italiano Malattie Ematologiche dell'Adulto, Acute Leukemia Working Party). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98: 239-246, 2013.","DOI":"10.3324\/haematol.2012.072645"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Herling M, Jones D. CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 127: 687-700, 2007.","DOI":"10.1309\/FY6PK436NBK0RYD4"},{"key":"4","unstructured":"4. Pileri A, Delfino C, Grandi V, Agostinelli C, Pileri SA, Pimpinelli N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. G Ital Dermatol Venereol 147: 603-608, 2012."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Novel therapeutic approaches in blastic plasmacytoid dendritic cell neoplasm (BPDCN): era of targeted therapy. Clin Lymphoma Myeloma Leuk 21: 734-740, 2021.","DOI":"10.1016\/j.clml.2021.05.018"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sapienza MR, Pileri A, Derenzini E, et al. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers (Basel) 11: 595, 2019.","DOI":"10.3390\/cancers11050595"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28: 823-829, 2014.","DOI":"10.1038\/leu.2013.283"},{"key":"8","unstructured":"8. Pemmaraju N, Kantarjian HM, Khoury JD, et al. Long-term outcomes in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 130: 3855, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Khwaja R, Daly A, Wong M, Mah\u00e9 E, Cerquozzi S, Owen C. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases. Leuk Lymphoma 57: 2720-2722, 2016.","DOI":"10.3109\/10428194.2016.1160084"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Laribi K, Denizon N, Ghnaya H, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol 93: 81-85, 2014.","DOI":"10.1111\/ejh.12294"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 7: 156-164, 2017.","DOI":"10.1158\/2159-8290.CD-16-0999"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93: 401-407, 2018.","DOI":"10.1002\/ajh.25000"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Condorelli A, Matteo C, Leotta S, et al. Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement. Cancer Chemother Pharmacol 89: 267-270, 2022.","DOI":"10.1007\/s00280-021-04356-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gangat N, Konopleva M, Patnaik MM, et al. Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 97: E62-E67, 2022.","DOI":"10.1002\/ajh.26417"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133: 7-17, 2019.","DOI":"10.1182\/blood-2018-08-868752"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/17\/62_0318-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T23:33:27Z","timestamp":1693611207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/17\/62_0318-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":15,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0318-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"0318-22"}}